What chief medical officer Patrick Horn called "the last piece of data that we need" to make an NDA submission arrived for Tetraphase Pharmaceuticals Inc. in the form of positive topline data from the phase III trial called IGNITE4, testing the company's intravenous (I.V.), twice-daily flourocycline antibiotic eravacycline compared with meropenem for complicated intra-abdominal infections (cIAI).